European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

Completed

• Conditions: Acute Bipolar Manic Episode

• Registration Number: NCT01239589
• Lead Sponsor: AstraZeneca

Brief Summary

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-10
• Study First Submitted QC: 2010-11-10
• Study First Posted: 2010-11-11
• Status Verified: 2011-03
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Last Update Submitted: 2011-03-28
• Last Update Posted: 2011-03-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1280

Inclusion Criteria

• Patients diagnosed with Bipolar Disorder (ICD-10).
• Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
• Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion Criteria

• Patients in which BD is not the main reason for hospitalization
• Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
• Patients receiving both quetiapine IR and XR during the same hospitalization period.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Length of hospital stay

Secondary Outcome Measures

Name	Time	Method
Use of resources
Treatments used
Demographics

Trial Locations

Locations (1)

Research Site; 🇬🇧 Newcastle (Upon Tyne), United Kingdom